AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19759186
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy with concurrent chemotherapy
Trial: 17913002
Drug: Control formulations
RxNorm normalized name: nut.tx, weight loss-control formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formulations (various enzymes and antibacterial agents)
Trial: 9106921
Drug: Conformal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal treatment with customized blocks, median high-dose volume (HDV) of 689 cm3
Trial: 9106921
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with rectangular fields, median high-dose volume (HDV) of 792 cm3
Trial: 8258043
Drug: Etidronate 10
RxNorm normalized name: etidronate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 10 mg/kg/day
Trial: 28738258
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (n=80)
Trial: 28738258
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus chemotherapy (n=74)
Trial: 16254147
Drug: High-dose DAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DAT (daunorubicin, cytarabine, and thioguanine)
Trial: 9322479
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg plus metoclopramide 10 mg (Group M2)
Trial: 30394347
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with dexmedetomidine (2 μg/mL)
Trial: 24496455
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of oral anticoagulants
Trial: 24496455
Drug: OAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC with antiplatelets (aspirin or clopidogrel)
Trial: 15200742
Drug: Chlorhexidine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.5% vaginal gel (CHX-VG), 2.5 g, daily for 7 days
Trial: 15200742
Drug: Metronidazole vaginal
RxNorm normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal tablets 500 mg (M), daily for 7 days
Trial: 15200742
Drug: Chlorhexidine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.5% vaginal gel (CHX-VG)
Trial: 9692706
Drug: Any gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any gastric antisecretory drug (mean duration 10.1 years, range 0.7-21 years)
Trial: 29901296
Drug: 5-reductase inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-reductase inhibitor (5-ARI) Pentester 5 mg once daily
Trial: 29901296
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 5-ARI (Penester 5 mg once daily) and blocker (Fokusin 0.4 mg once daily)
Trial: 20123670
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (120 mg EGb 761 twice daily)
Trial: 17187496
Drug: Estrogen as
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen as an adjunct to standard antipsychotic medication
Trial: 15713726
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with alendronate and hormone replacement therapy
Trial: 12016085
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave therapy (1000 impulses at 14 kV)
Trial: 10560786
Drug: Transdermal 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐estradiol (50 microg/day, transdermal) and norethisterone acetate (2.5 mg/day, orally)
Trial: 10560786
Drug: Transdermal 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐estradiol
Trial: 8919710
Drug: Carbamazepine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (400 to 800 mg, mean 683 mg)
Trial: 1871801
Drug: CsA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA and steroids alone
Trial: 31271526
Drug: Etanercept and
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept and methotrexate in combination
Trial: 28841667
Drug: D-aspartic acid
RxNorm normalized name: (3S)-3-methyl-D-aspartic acid
DrugBank: D-Aspartic Acid (DB02655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-aspartic acid (6 g/d)
Trial: 19776136
Drug: Only 500
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only 500 mL skim milk/d (M)
Trial: 7491044
Drug: Neither treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither treatment (control group)
Trial: 8279224
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen exposure (2.8 atm, 100% O2, 60 min daily for 10 days)
Trial: 3519240
Drug: 0.170 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.170 mg/kg bambuterol b.i.d.
Trial: 3291897
Drug: Pinacidil or
RxNorm normalized name: pinacidil Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil or hydralazine as monotherapy or with propranolol and/or hydrochlorothiazide
Trial: 12621507
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir 500 mg twice daily until resolution of neutropenia
Trial: 12621507
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 600 mg every 6 h until resolution of neutropenia or acyclovir 125 mg/m(2) intravenously every 6 h
Trial: 3807474
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg piretanide with 40 mg hyoscine‐N‐butylbromide (HNB)
Trial: 3807474
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg piretanide without HNB
Trial: 16431002
Drug: Kaneka Q10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaneka Q10 300 mg/day
Trial: 16431002
Drug: Kaneka Q10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaneka Q10 600 mg/day
Trial: 7901059
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 g oral dose)
Trial: 3528725
Drug: Naftidrofurylhydrogenoxalate (Dusodril)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofurylhydrogenoxalate (Dusodril) as adjunctive therapy
Trial: 3528725
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dextran‐40 infusions)
Trial: 23410527
Drug: Aromatherapy inhalation
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy inhalation
Trial: 8911878
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 micrograms three times daily, total dose 150 micrograms)
Trial: 8911878
Drug: Octreotide (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (62.5 micrograms continuous infusion 24/h)
Trial: 8911878
Drug: Octreotide (112.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (112.5 micrograms continuous infusion 24/h)
Trial: 8911878
Drug: Octreotide (113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (113 micrograms continuous infusion)
Trial: 8911878
Drug: Octreotide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (all doses)
Trial: 1816439
Drug: Captopril, 50
RxNorm normalized name: Captopril, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 50 mg
Trial: 1816439
Drug: Prazosin, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin, 2 mg
Trial: 2455105
Drug: Nifedipine, 20
RxNorm normalized name: Nifedipine, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 20 mg
Trial: 6125198
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release aminophylline tablets
Trial: 6125198
Drug: Inhaled rimiterol
RxNorm normalized name: rimiterol
DrugBank: Rimiterol (DB13559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled rimiterol
Trial: 27914903
Drug: Short-term psychoanalytical
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychoanalytical therapy
Trial: 14991686
Drug: Bromazepam 6
RxNorm normalized name: bromazepam 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 6 mg from Medley SA Indústria Farmacêutica (test formulation)
Trial: 11713622
Drug: 0.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg (placebo)
Trial: 7491369
Drug: Imipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (150 mg/day for at least 4 consecutive weeks)
Trial: 535860
Drug: Piracetam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (10 g i.v./h)
Trial: 535860
Drug: Laevulose (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laevulose (placebo infusion)
Trial: 20456192
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 0.1%
Trial: 9422303
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with lidocaine 50 mg/ml 1.5‐2 ml in 7.5% glucose through a 27‐G Quincke needle (Group S)
Trial: 9422303
Drug: Propofol anaesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anaesthesia with a bolus induction of 2 mg/kg followed by infusion (Group P)
Trial: 8284627
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tetracycline 2 g, metronidazole 750 mg, bismuth subsalicylate 5 or 8 tablets) plus ranitidine 300 mg
Trial: 8284627
Drug: Ranitidine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine alone 300 mg
Trial: 29458317
Drug: 1 kcal/mL
RxNorm normalized name: lactose-reduced food 0.06 gram-1 kcal/mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 kcal/mL enteral nutrition formulation
Trial: 10406828
Drug: Glyburide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (20 mg/d)
Trial: 8926537
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of red pepper
Trial: 8926537
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of red pepper with propranolol
Trial: 7107086
Drug: Spironothiazid (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironothiazid (50 mg spironolactone, 50 mg hydrochlorothiazide)
Trial: 7107086
Drug: Aldactone dragees
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldactone dragees (50 mg) plus Esidrex tablets (25 mg)
Trial: 29654023
Drug: Erlotinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib monotherapy
Trial: 30293332
Drug: Single aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single aspirin
Trial: 9180622
Drug: Active biofeedback
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active biofeedback treatment
Trial: 17584007
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily for 4 days prior to hypoxia exposure
Trial: 9474534
Drug: Complete denture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete denture therapy procedures
Trial: 9474534
Drug: Procedural research
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Procedural research in denture therapy
Trial: 7857356
Drug: pidotimod 400
RxNorm normalized name: pidotimod 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pidotimod 400 mg
Trial: 2509605
Drug: MOR‐22 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR‐22 and UFT (or FT‐207) in combination
Trial: 145237
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc
Trial: 26280756
Drug: Canagliflozin 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 25, 100, 200, or 400 mg (single dose and repeated doses for 14 days)
Trial: 22983502
Drug: Strengthening ties
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthening ties that provide social support but not drug support
Trial: 22983502
Drug: Reducing ties
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reducing ties that provide both drug and social support
Trial: 17045558
Drug: Six-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-dose regimen of artemether-lumefantrine
Trial: 12938592
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled intravenous morphine
Trial: 16422731
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs
Trial: 21154265
Drug: L-arginine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (8 g/day)
Trial: 10716474
Drug: Training group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training group (daily handgrip training)
Trial: 10716474
Drug: L-arginine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine + Training
Trial: 1490801
Drug: Trapidil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapidil (200 mg orally, 100 mg intravenously)
Trial: 3987781
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg) before standardized breakfast (Phase A)
Trial: 3987781
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg) after standardized breakfast (Phase B)
Trial: 15072715
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg twice daily
Trial: 9772584
Drug: Zusanli point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zusanli point immunotherapy (ZPIT)
Trial: 9772584
Drug: Conventional desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional desensitization therapy
Trial: 1929138
Drug: Standard drainage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drainage (drain removed when fluid was less than 20 ml per day)
Trial: 6812337
Drug: Clebopride 1
RxNorm normalized name: clebopride
DrugBank: Clebopride (DB13511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clebopride 1 mg orally at 09.00 h
Trial: 25028414
Drug: Intravenous baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous baclofen (3 mg and 5 mg)
Trial: 25028414
Drug: Oral baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral baclofen (5 mg and 10 mg)
Trial: 17020437
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (IR MPH) dosed three times daily
Trial: 17020437
Drug: Non-stimulant treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-stimulant treatments (e.g., atomoxetine)
Trial: 14769594
Drug: Latanoprost (0.005%)
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost (0.005%) once daily
Trial: 2865710
Drug: Timolol (0.5%)
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol (0.5%) twice daily
Trial: 31251545
Drug: Subdermal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal injection
Trial: 11057406
Drug: Peritumoural injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritumoural injection
Trial: 8130709
Drug: Brief nurse‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief nurse‐administered anti‐smoking intervention
Trial: 3298071
Drug: Acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (800 mg, two 400 mg tablets, five times daily for seven days)
Trial: 3298071
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, five times daily for seven days)
Trial: 28259273
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral placebo 2 hours prior to procedure, then placebo twice a day for 5 days)
Trial: 26342502
Drug: Sulfur 10%
RxNorm normalized name: SULFUR 10% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfur 10% ointment applied for three successive days
Trial: 23963058
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg twice daily)
Trial: 23963058
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (600 mg twice daily)
Trial: 21654688
Drug: Irinotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan at starting doses of 180 mg m(‐2) for *1/*1, 110 mg m(‐2) for *1/*28, and 90 mg m(‐2) for *28/*28 genotypes; escalated to 450 mg m(‐2) for *1/*1, 390 mg m(‐2) for *1/*28, and 150 mg m(‐2) for *28/*28 genotypes.
Trial: 21654688
Drug: Recommended dose
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dose of 180 mg m(‐2) for irinotecan in FOLFIRI.
Trial: 15179649
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of hyaluronate
Trial: 9751463
Drug: Oral glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoid treatment
Trial: 7516979
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (transurethral microwave therapy)
Trial: 7516979
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (transurethral microwave therapy) after sham treatment
Trial: 3190622
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dexamethasone orally every 6 h (starting 1 h before take-off)
Trial: 3190622
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone orally or intramuscularly every 6 h for 24 h
Trial: 28401564
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg naltrexone daily for 10 weeks
Trial: 28401564
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 10 weeks
Trial: 23419135
Drug: Percentage format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage format (e.g. 'affects 25% of people')
Trial: 23419135
Drug: Frequency format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency format (e.g. 'affects 1 in 4 people')
Trial: 21205874
Drug: Repaglinide (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (6 mg daily)
Trial: 16534885
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (800 mg) per month for 6 cycles
Trial: 8040707
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard oral hygiene)
Trial: 3541622
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of percutaneous estradiol
Trial: 3541623
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (200 mg) for 12 days of each cycle during the second year
Trial: 31432556
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg three times daily
Trial: 17561259
Drug: Normal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal group (no treatment)
Trial: 27534634
Drug: Actual supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual supplement provided (IFA)
Trial: 27534634
Drug: Actual supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual supplement provided (MMN)